We thank Drs. Musolino and Supino ([@R1]) for their useful commentary on the role of lung ultrasound in the diagnosis and management of children with coronavirus disease 2019 (COVID-19) ([@R2]), recently published in *Pediatric Critical Care Medicine*. From a number of perspectives, ultrasound can be seen as a very valuable tool in the management of these patients. The ability to limit providers in patients' rooms is hugely important, so if valuable diagnostic information and management guidance can be obtained without new added machinery or individuals, this would be wonderful. One of the challenges in its wide-scale implementation is ensuring adequate training of users and inter-operator standardization ([@R3]). Given the limited currently available data on its role in children with COVID-19, we look forward to seeing data emerge on its ability to discriminate severity and guide management in children with COVID-19.
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